Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06449937
Status:
RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-06-04
Brief Title:
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
Sponsor:
Anhui Provincial Hospital
Organization:
Anhui Provincial Hospital
Study Overview
Official Title:
Analysis of the Efficacy of Local Liver Treatment for Multi-organ Colorectal Cancer Metastases A Prospective Multicenter Non-randomized Concurrent Controlled Study
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer whether it can benefit the prognosis and explore the risk factors related to the prognosis
Detailed Description:
Primary objective
1To determine the survival benefit of local radical resection of liver metastases in patients with resectable liver and controllable extrahepatic metastases from colorectal cancer
Secondary objectives
1 To explore the prognosis-related risk factors in patients with colorectal cancer liver metastases combined with extrahepatic metastases
2 To assess patients quality-of-life in each treatment group with questionnaires
3 To evaluate the safety of the treatment in each treatment group
Grouping Method Patients are assigned to 1 of 2 groups according to their willingness
GROUP I Patients undergo radical local treatment of liver metastases hepatectomy ablation combined with systemic therapy
GROUP II Patients receive Systemic therapy only or combined local interventions TACE HAIC
Patients are followed up every 3 months up to 2 years
1To determine the survival benefit of local radical resection of liver metastases in patients with resectable liver and controllable extrahepatic metastases from colorectal cancer
Secondary objectives
1 To explore the prognosis-related risk factors in patients with colorectal cancer liver metastases combined with extrahepatic metastases
2 To assess patients quality-of-life in each treatment group with questionnaires
3 To evaluate the safety of the treatment in each treatment group
Grouping Method Patients are assigned to 1 of 2 groups according to their willingness
GROUP I Patients undergo radical local treatment of liver metastases hepatectomy ablation combined with systemic therapy
GROUP II Patients receive Systemic therapy only or combined local interventions TACE HAIC
Patients are followed up every 3 months up to 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None